Key Stats
Key stats represent essential financial metrics and indicators used to evaluate a company's performance and potential investment opportunities.
Stock Score/grades
The Stock Score/Grades evaluate bankruptcy risk and assess the financial strength and fundamental health of a company
- Altman Z Score -21.32
- Piotroski Score 2.00
- Grade Buy
- Symbol (GALT)
- Company Galectin Therapeutics Inc.
- Price $2.70
- Changes Percentage (-2.53%)
- Change -$0.07
- Day Low $2.65
- Day High $2.85
- Year High $4.27
Galectin Therapeutics Inc., a clinical stage biopharmaceutical company, engages in the research and development of therapies for fibrotic, cancer, and other diseases. The company's lead product candidate is belapectin (GR-MD-02) galectin-3 inhibitor, a galactoarabino-rhamnogalacturonan polysaccharide polymer that is in Phase III clinical trial for the treatment of liver fibrosis associated with fatty liver disease and non-alcoholic steatohepatitis cirrhosis, as well as for the treatment of cancer. It also engages in developing GM-CT-01, which is in pre-clinical development stage for the treatment of cardiac and vascular fibrosis, as well as focuses on developing belapectin for the treatment of psoriasis, and lung and kidney fibrosis. The company, through its Galectin Sciences, LLC, which is a collaborative joint venture co-owned by SBH Sciences, Inc., to research and development of small organic molecule inhibitors of galectin-3 for oral administration. The company was formerly known as Pro-Pharmaceuticals, Inc. and changed its name to Galectin Therapeutics, Inc. in May 2011. Galectin Therapeutics Inc. was founded in 2000 and is based in Norcross, Georgia.
- Last Earnings
- Ex-Dividend for 5/16 Dividend
- Dividend Payable
- Today N/A
- Next Earnings (Estimated) 03/27/2025
- Fiscal Year End N/A
- Average Stock Price Target $0.00
- High Stock Price Target $0.00
- Low Stock Price Target $0.00
- Potential Upside/Downside N/A
- Consensus Rating Sell
- Rating Score (0-4) N/A
- Research Coverage N/A
- EPS (Most Recent Fiscal Year) -$0.74
- Trailing P/E Ratio -3.51
- Forward P/E Ratio -3.51
- P/E Growth -3.51
- Net Income $-41,066,000
Income Statement
Quarterly
Annual
Latest News of GALT
The Latest News section aggregates recent news posts from various news outlets, offering a comprehensive overview of the most recent developments related to the topic.
-
Will AI driven legaltech replace lawyers or simply create a massive productivity boost?
GenAI, like OpenAI's ChatGPT, is revolutionizing industries, including law. Legaltech startups are impacting traditional legal processes. Despite the rise of AI in law firms, human expertise remains v...
By Yahoo! Finance | 6 days ago -
Galectin Therapeutics Inc.'s (NASDAQ:GALT) largest shareholders are retail investors with 57% ownership, insiders own 20%
Retail investors own 57% of Galectin Therapeutics stock, followed by insiders at 20%, and institutions at a significant stake. Hedge funds control 9.5% of shares. Analyst sentiments and insider owners...
By Yahoo! Finance | 3 months ago
